WALTHAM, Mass. / Dec 19, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 a.m. PT in San Francisco, CA.
President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities.
To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
| Last Trade: | US$90.42 |
| Daily Change: | -1.49 -1.62 |
| Daily Volume: | 1,437,884 |
| Market Cap: | US$11.000B |
April 30, 2025 March 20, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
